<?xml version='1.0' encoding='utf-8'?>
<document id="28569378"><sentence text="Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction."><entity charOffset="0-12" id="DDI-PubMed.28569378.s1.e0" text="Cyclosporine" /><entity charOffset="25-33" id="DDI-PubMed.28569378.s1.e1" text="ketamine" /><pair ddi="false" e1="DDI-PubMed.28569378.s1.e0" e2="DDI-PubMed.28569378.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s1.e0" e2="DDI-PubMed.28569378.s1.e1" /></sentence><sentence text="Cyclosporine A (CsA) is an immunosuppressive drug commonly used in organ transplant patients to prevent allograft rejections"><entity charOffset="0-14" id="DDI-PubMed.28569378.s2.e0" text="Cyclosporine A" /><entity charOffset="16-19" id="DDI-PubMed.28569378.s2.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28569378.s2.e0" e2="DDI-PubMed.28569378.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s2.e0" e2="DDI-PubMed.28569378.s2.e1" /></sentence><sentence text=" Ketamine is a pediatric anesthetic that noncompetitively inhibits the calcium-permeable N-methyl-d-aspartic acid receptors"><entity charOffset="1-9" id="DDI-PubMed.28569378.s3.e0" text="Ketamine" /><entity charOffset="71-78" id="DDI-PubMed.28569378.s3.e1" text="calcium" /><entity charOffset="89-113" id="DDI-PubMed.28569378.s3.e2" text="N-methyl-d-aspartic acid" /><pair ddi="false" e1="DDI-PubMed.28569378.s3.e0" e2="DDI-PubMed.28569378.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s3.e0" e2="DDI-PubMed.28569378.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28569378.s3.e0" e2="DDI-PubMed.28569378.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28569378.s3.e1" e2="DDI-PubMed.28569378.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28569378.s3.e1" e2="DDI-PubMed.28569378.s3.e2" /></sentence><sentence text=" Adverse drug-drug interaction effects between ketamine and CsA have been reported in mammals and humans"><entity charOffset="47-55" id="DDI-PubMed.28569378.s4.e0" text="ketamine" /><entity charOffset="60-67" id="DDI-PubMed.28569378.s4.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28569378.s4.e0" e2="DDI-PubMed.28569378.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s4.e0" e2="DDI-PubMed.28569378.s4.e1" /></sentence><sentence text=" However, the mechanism of such drug-drug interaction is unclear" /><sentence text=" We have previously reported adverse effects of combination drugs, such as verapamil/ketamine and shown the mechanism through intervention by other drugs in zebrafish embryos"><entity charOffset="75-84" id="DDI-PubMed.28569378.s6.e0" text="verapamil" /><entity charOffset="85-93" id="DDI-PubMed.28569378.s6.e1" text="ketamine" /><pair ddi="false" e1="DDI-PubMed.28569378.s6.e0" e2="DDI-PubMed.28569378.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s6.e0" e2="DDI-PubMed.28569378.s6.e1" /></sentence><sentence text=" Here, we show that ketamine and CsA in combination produce developmental toxicity even leading to lethality in zebrafish larvae when exposure began at 24â€‰h post-fertilization (hpf), whereas CsA did not cause any toxicity on its own"><entity charOffset="20-28" id="DDI-PubMed.28569378.s7.e0" text="ketamine" /><entity charOffset="33-36" id="DDI-PubMed.28569378.s7.e1" text="CsA" /><entity charOffset="191-193" id="DDI-PubMed.28569378.s7.e2" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28569378.s7.e0" e2="DDI-PubMed.28569378.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s7.e0" e2="DDI-PubMed.28569378.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28569378.s7.e0" e2="DDI-PubMed.28569378.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28569378.s7.e1" e2="DDI-PubMed.28569378.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28569378.s7.e1" e2="DDI-PubMed.28569378.s7.e2" /></sentence><sentence text=" We also demonstrate that acetyl l-carnitine (ALCAR) completely reversed the adverse effects"><entity charOffset="26-44" id="DDI-PubMed.28569378.s8.e0" text="acetyl l-carnitine" /><entity charOffset="46-51" id="DDI-PubMed.28569378.s8.e1" text="ALCAR" /><pair ddi="false" e1="DDI-PubMed.28569378.s8.e0" e2="DDI-PubMed.28569378.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s8.e0" e2="DDI-PubMed.28569378.s8.e1" /></sentence><sentence text=" Both ketamine and CsA are CYP3A4 substrates"><entity charOffset="6-14" id="DDI-PubMed.28569378.s9.e0" text="ketamine" /><entity charOffset="19-26" id="DDI-PubMed.28569378.s9.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28569378.s9.e0" e2="DDI-PubMed.28569378.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s9.e0" e2="DDI-PubMed.28569378.s9.e1" /></sentence><sentence text=" Although ketamine and CsA independently altered the expression of the hepatic marker CYP3A65, a zebrafish ortholog of human CYP3A4, both drugs together induced further increase in CYP3A65 expression"><entity charOffset="10-18" id="DDI-PubMed.28569378.s10.e0" text="ketamine" /><entity charOffset="23-30" id="DDI-PubMed.28569378.s10.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28569378.s10.e0" e2="DDI-PubMed.28569378.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s10.e0" e2="DDI-PubMed.28569378.s10.e1" /></sentence><sentence text=" In the presence of ALCAR, however, CYP3A65 expression was normalized"><entity charOffset="20-22" id="DDI-PubMed.28569378.s11.e0" text="ALCAR" /></sentence><sentence text=" ALCAR has been shown to prevent ketamine toxicity in mammal and zebrafish"><entity charOffset="33-41" id="DDI-PubMed.28569378.s12.e0" text="ketamine" /><entity charOffset="1-8" id="DDI-PubMed.28569378.s12.e1" text="ALCAR" /><pair ddi="false" e1="DDI-PubMed.28569378.s12.e1" e2="DDI-PubMed.28569378.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28569378.s12.e1" e2="DDI-PubMed.28569378.s12.e0" /></sentence><sentence text=" In conclusion, CsA exacerbated ketamine toxicity and ALCAR reversed the effects"><entity charOffset="32-40" id="DDI-PubMed.28569378.s13.e0" text="ketamine" /><entity charOffset="16-23" id="DDI-PubMed.28569378.s13.e1" text="CsA" /><entity charOffset="54-61" id="DDI-PubMed.28569378.s13.e2" text="ALCAR" /><pair ddi="false" e1="DDI-PubMed.28569378.s13.e1" e2="DDI-PubMed.28569378.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28569378.s13.e1" e2="DDI-PubMed.28569378.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s13.e1" e2="DDI-PubMed.28569378.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28569378.s13.e0" e2="DDI-PubMed.28569378.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s13.e0" e2="DDI-PubMed.28569378.s13.e2" /></sentence><sentence text=" These results, providing evidence for the first time on the reversal of the adverse effects of CsA/ketamine interaction by ALCAR, would prove useful in addressing potential occurrences of such toxicities in humans"><entity charOffset="100-108" id="DDI-PubMed.28569378.s14.e0" text="ketamine" /><entity charOffset="96-103" id="DDI-PubMed.28569378.s14.e1" text="CsA" /><entity charOffset="124-131" id="DDI-PubMed.28569378.s14.e2" text="ALCAR" /><pair ddi="false" e1="DDI-PubMed.28569378.s14.e1" e2="DDI-PubMed.28569378.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28569378.s14.e1" e2="DDI-PubMed.28569378.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s14.e1" e2="DDI-PubMed.28569378.s14.e2" /><pair ddi="false" e1="DDI-PubMed.28569378.s14.e0" e2="DDI-PubMed.28569378.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28569378.s14.e0" e2="DDI-PubMed.28569378.s14.e2" /></sentence><sentence text=" Published 2017" /><sentence text=" This article is a U" /><sentence text="S" /><sentence text=" Government work and is in the public domain in the USA" /><sentence text="" /></document>